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The NADPH oxidase (Nox) family of proteins is comprised of seven members, including
Noxes1–5 and the Duoxes 1 and 2. Nox4 is readily distinguished from the other Nox
isoforms by its high level of expression in cardiovascular tissues and unique enzymatic
properties. Nox4 is constitutively active and the amount of reactive oxygen species (ROS)
contributed by Nox4 is primarily regulated at the transcriptional level although there is
recent evidence for post-translational control. Nox4 emits a different pattern of ROS and
its subcellular localizations, tissue distribution and influence over signaling pathways is
different from the other Nox enzymes. Previous investigations have revealed that Nox4
is involved in oxygen sensing, vasomotor control, cellular proliferation, differentiation,
migration, apoptosis, senescence, fibrosis, and angiogenesis. Elevated expression of
Nox4 has been reported in a number of cardiovascular diseases, including atherosclerosis,
pulmonary fibrosis, and hypertension, cardiac failure and ischemic stroke. However, many
important questions remain regarding the functional significance of Nox4 in health and
disease, including the role of Nox4 subcellular localization and its downstream targets.
The goal of this review is to summarize the recent literature on the genetic and
enzymatic regulation, subcellular localization, signaling pathways, and the role of Nox4
in cardiovascular disease states.
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INTRODUCTION
Reactive oxygen species (ROS) refer to a group of small reac-
tive molecules that include superoxide (O·−2 ), hydrogen peroxide
(H2O2), hydroxyl (·OH−), and hypochlorite (OCl−·) (Bedard
and Krause, 2007). ROS are a consequence of aerobic metabolism
and react avidly with other molecules, cellular lipids, proteins,
and nucleic acids. Over time, cells have evolved strategies to reg-
ulate ROS levels to ensure the fidelity of physiological processes
and survival. Low to moderate levels of ROS have been shown
to contribute to important functions, such as cell differentiation,
migration, adhesion, senescence, growth, and apoptosis. In con-
trast, a variety of diseases, such as cancer, neurological, and most
relevant to this review, cardiovascular disease, are associated with
elevated ROS levels (Lambeth, 2007; Lassegue and Griendling,
2010). A significant source of cellular ROS is the NADPHoxidases
(Noxs) family of enzymes.
All five Nox enzymes, including Nox4 are dual heme contain-
ing transmembrane oxidoreductases that span the membrane six
times (see Figure 1). Catalytic activity originates with the bind-
ing of NADPH to a C-terminal site and the transfer of electrons
through FAD to the two heme residues and, ultimately, to molec-
ular oxygen to produce ROS. The mechanisms governing the
activation of Noxes and production of ROS are different. The
Abbreviations: VSMC, vascular smooth muscle cells; ER, endoplasmic reticulum;
PM, plasma membrane; O·−2 , superoxide; H2O2, hydrogen peroxide; NO, nitric
oxide.
activation of Nox1–3 are analogous, and involves a combination
of phosphorylation and protein–protein interactions. The sub-
units of Nox1–3 include p22phox, p40phox, p47phox, p67phox,
NOXO1, and NOXA1 and the small G-proteins, Rac and Rap1a
(Lassegue and Clempus, 2003; Griendling, 2004; Lassegue and
Griendling, 2010). The cooperative binding of these subunits to
the transmembrane Nox enzymes initiates electron transfer and
is triggered by various stimuli including Angiotensin II. Nox5
does not require cytosolic or membrane subunits and has been
reviewed in detail elsewhere (Fulton, 2009).
ENZYMATIC PROPERTIES OF Nox4
Nox4 colocalizes with and directly binds the integral membrane
protein p22phox which is necessary for Nox4 activity (Bedard
and Krause, 2007) to stabilize p22phox expression (Martyn et al.,
2006). The binding and activation of Nox4 by p22phox does not
depend on the proline rich region of p22phox which is important
in the regulation of Nox1–3 (Kawahara et al., 2005). A further dis-
tinction is that unlike Nox1–3, Nox4 does not require the binding
of cytosolic proteins for ROS production (Martyn et al., 2006) and
instead produces ROS constitutively. This is due to unique charac-
teristics of the C-terminus of Nox4 that facilitates the constitutive
transfer of electrons fromNADPH to FAD (Nisimoto et al., 2010).
Yet another distinguishing feature of Nox4 is the inability to detect
O·−2 production in Nox4 transfected cells. Instead, robust produc-
tion of H2O2 can be detected which contrasts from a mixture
of O·−2 and H2O2 from Nox1–3 to Nox5 (Martyn et al., 2006;
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FIGURE 1 | A central role for Nox4 in the regulation of vascular cell
function and cardiovascular disease. FORM: Nox4 spans the membrane
six times and produces hydrogen peroxide constitutively due to a histidine
residue in the last transmembrane loop (E-loop). These enzymatic properties
influence the FUNCTION of the cell via various signaling intermediaries. The
expression level of Nox4 can be REGULATED via a number of stimuli and
soluble factors which activate distinct transcription factors. These events
have been proposed to influence various DISEASE processes.
Serrander et al., 2007; Brandes et al., 2011). The mechanism
underlying the preferential production of H2O2 vs. O
·−
2 is pro-
posed to be a highly conserved histidine residue in the E-loop of
Nox4 that promotes the rapid dismutation of O·−2 before it leaves
the enzyme (Takac et al., 2011). Based on this information, prior
reports of O·−2 production from endogenous Nox4 expressed in
native cells are difficult to reconcile (Geiszt et al., 2000; Kuroda
et al., 2005). It is likely that this issue stems from themethods used
to detect different ROS and the concurrent expression of multiple
Nox enzymes in native cells compared to the presence of unique
or additional features of native cells than enable O·−2 production
from Nox4. A further unique feature of Nox4 is its insensitivity
to inhibitors of Hsp90 compared to the stimulus-dependent Nox
enzymes. Nox1–3 and 5 interact with Hsp90 which facilitates O·−2
release and maintains protein stability (Chen et al., 2011). Hsp90
binds directly to the C-terminal region of Nox5 and binding to
Nox1,3 is inferred from studies using chimeric proteins. Chimeric
proteins that comprise the N-terminal region of Nox4 and the
C-terminal region of Nox1 and 3 are sensitive to Hsp90 inhibitors.
In contrast, fusion of the N-terminal region of Nox1 or Nox3
to the C-terminal region of Nox4 results in enzymes that are no
longer sensitive to Hsp90 inhibition. Interestingly, these chimeric
proteins produce only H2O2 suggesting that the C-terminal of
Nox1–3 and 5 and chaperone-dependent folding are important
for O·−2 release (Chen et al., 2011).
Nox4 VARIANTS, EXPRESSION, AND GENETIC VARIATION
The gene encoding Nox4 is found on chromosome 11 and con-
tains 34 introns, and is transcribed into 16 spliced and 1 unspliced
mRNAs. Of these variants, at least four splice variants encoding
proteins have been reported in cells (Goyal et al., 2005). Only one
of these variants was active as assessed by ROS production, but the
mechanisms by which this variant generates ROS remain unclear
as it lacks most of the transmembrane regions and part of the
FAD binding region. Nox4 was originally identified in the kidney
(Geiszt et al., 2000; Shiose et al., 2001) and in addition to cardio-
vascular tissues discussed below, it is expressed in hematopoietic
stem cells (Piccoli et al., 2005), osteoclasts (Yang et al., 2001,
2004), keratinocytes (Chamulitrat et al., 2004), melanoma cells
(Brar et al., 2002), neurons (Vallet et al., 2005; Kleinschnitz
et al., 2010), adipocyte (Kanda et al., 2011), embryonic stem cells
(Bartsch et al., 2011), chondrocytes (Grange et al., 2006; Kim
et al., 2010), hepatic stellate cells (Ikeda et al., 2011), epithe-
lial cells (Carnesecchi et al., 2011), and podocytes (Piwkowska
et al., 2011). Using the human Nox4 standard gene sequence
for comparison, approximately 2385 single nucleotide polymor-
phism (SNP) sites were found in the genomic DNA region of
Nox4, and 45 SNP sites in the gene coding region. One of these
sites conferred a frame shift mutation. The sequence variations
described for Nox4 may affect gene replication or transcription,
and possibly enzymatic function and ROS production. Therefore,
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it is possible they may contribute to the occurrence and devel-
opment of disease. However, correlations between the genetic
polymorphisms of Nox4 in different populations and disease
related variations in Nox4 activity and or expression are poorly
understood. Such associations would be aided by genetic stud-
ies investigating the relationship between Nox4 expression and
function in diseases related to elevated ROS levels.
EXPRESSION OF Nox4 IN BLOOD VESSELS AND THE HEART
The presence of Nox4 in vascular cells was documented soon after
its initial discovery in murine and human kidney (Geiszt et al.,
2000; Lambeth et al., 2000; Cheng et al., 2001; Shiose et al., 2001)
and osteroclasts (Yang et al., 2001). Nox4 mRNA was found to be
an abundant transcript in cultured rat and human aortic vascular
smooth muscle cells (VSMC) (Lassegue et al., 2001; Touyz et al.,
2002). In the years, since its discovery there has been considerable
variation and controversy in identifying the principal location(s)
of Nox4 in intact blood vessels. Using antisense riboprobes and a
polyclonal antibody, Nox4 was identified primarily in the media
of control rat carotid arteries and staining was most intense in the
neointima of balloon injured vessels (Szocs et al., 2002). Similar
staining patterns with robust staining of cells in the neointima
have been observed in atherosclerotic human coronary arteries
(Sorescu et al., 2002). Mittal et al. have shown, using both anti
Nox4 antibodies and in situ hybridization, that Nox4 is primarily
expressed in the medial layer of pulmonary blood vessels in both
mice and humans (Mittal et al., 2007). In blood vessels, Nox4 is by
far the most abundant Nox transcript (>1000 fold copy number
over that of Nox1 and Nox2) (Matsuno et al., 2005). This is sup-
ported by studies in cultured cells which show that Nox4 mRNA
is expressed at copy numbers greater than 10–1000 times that
of Nox2 (Sorescu et al., 2002; Ago et al., 2004) and greater than
1000 times that of Nox1 (Dikalov et al., 2008). This data would
suggest that Nox4 is the most abundant Nox isoform in the vas-
culature. However, one must be mindful that mRNA levels may
not accurately reflect protein expression levels of the various Nox
isoforms. In addition to VSMC (Touyz et al., 2002; Ellmark et al.,
2005; Sturrock et al., 2006; Jay et al., 2008; Ismail et al., 2009)
Nox4 is present in multiple cell types including endothelial cells
and fibroblasts (Sorescu et al., 2002; Ago et al., 2004; Van Buul
et al., 2005). In contrast to the early imaging studies, quantitative
analysis of the relative level of Nox4mRNA expression in cultured
cells revealed that smooth muscle cells express proportionally, the
least amount of Nox4, with higher levels found in endothelial cells
and fibroblasts (Sorescu et al., 2002; Ago et al., 2004; Schroder
et al., 2012). More recent studies using different Nox4 antibod-
ies support this relationship and show that the majority of Nox4
staining in the intact aorta is confined to the endothelial cell layer
(Craige et al., 2011; Ray et al., 2011). A caveat to these findings
is that in intact blood vessels, the adventitial layer is frequently
underrepresented or removed (Szocs et al., 2002). Adventitial
staining has been observed in coronary blood vessels (Sorescu
et al., 2002) and in rat aortic and human pulmonary fibroblasts
(Haurani et al., 2008; Hecker et al., 2009; Amara et al., 2010).
Nox4 has also been reported in immune cells such asmacrophages
(Lee et al., 2010) which can also populate the adventitia, particu-
larly in inflammatory settings. The obligate Nox4 binding partner,
p22phox has been shown to exhibit a similar pattern of expres-
sion and is present in all cell layers in intact blood vessels and
cultured vascular cells (Ushio-Fukai et al., 1996; Azumi et al.,
1999; Szocs et al., 2002). Nox4 expression has been reported in
human andmouse cardiacmyocytes (Byrne et al., 2003; Ago et al.,
2010; Kuroda et al., 2010; Zhang et al., 2010). The relative abun-
dance of Nox4 in the cardiacmyocyte vs. vascular tissue is not well
defined. In sum, there a wealth of evidence that Nox4 is expressed
in all layers of the blood vessel and indeed all vascular and some
perivascular cell types. However, the abundance and location of
Nox4 in the respective cell types is likely to vary and be influenced
by factors such as the organism in question, intramural pressure,
inflammation, growth factors, oxygen concentration, and the type
of vascular bed. A greater appreciation of how Nox4 is contribut-
ing to cardiovascular function in conditions of health and disease
will need to be derived from imaging studies using well validated
tools and cellular markers.
REGULATION OF THE EXPRESSION AND ACTIVITY OF Nox4
A number of studies have shown that Nox4 is robustly upreg-
ulated in response to transforming growth factor-beta (TGF-β)
stimulation in a variety of cell types including aortic and pul-
monary smooth muscle cells, pulmonary and cardiac fibroblasts,
endothelial and embryonic kidney cells (Cucoranu et al., 2005;
Hu et al., 2005; Sturrock et al., 2006; Hecker et al., 2009; Ismail
et al., 2009; Xiao et al., 2009). Angiotensin II has been shown to
potently activate Nox1 and Nox2 and subunits in vascular cells
(Rajagopalan et al., 1996; Ushio-Fukai et al., 1996; Pagano et al.,
1997; Touyz et al., 2002; Matsuno et al., 2005), but the effects on
Nox4 expression are much less pronounced and perhaps indirect
(Lassegue et al., 2001; Mollnau et al., 2002; Byrne et al., 2003;
Cucoranu et al., 2005). These data suggest that vasoactive factors
that influence blood vessel function in distinct ways can couple to
specific Nox enzymes. Tumor necrosis factor-alpha is less specific
and can increase both Nox1, 2 and Nox4 activity and or expres-
sion in a variety of vascular cells (Anilkumar et al., 2008; Basuroy
et al., 2009; Moe et al., 2011). Other stimuli that induce Nox4
expression are endoplasmic reticulum (ER) stress (Pedruzzi et al.,
2004), shear stress (Hwang et al., 2003), carotid artery balloon
injury (Szocs et al., 2002), hypoxia and ischemia (Vallet et al.,
2005; Lu et al., 2010), and the activation of PKCα (Xu et al., 2008).
The down regulation of Nox4 expression has also been reported
in response to platelet-derived growth factor (PDGF) and per-
oxisome proliferator-activated receptor-gamma (PPAR-gamma)
ligands (Lassegue et al., 2001; Hwang et al., 2005), bone mor-
phogenic protein 4 (BMP4) (Lambeth et al., 2007) and serum
starvation of cultured cells (Peshavariya et al., 2009). A num-
ber of transcription factors have been shown to regulate Nox4
promoter activity including NFkB (Lu et al., 2010); SMAD2/3
(Sturrock et al., 2006), E2F (Zhang et al., 2008), HIF1α (Diebold
et al., 2010), and Nrf2 (Pendyala et al., 2011) and these pathways
are also likely dependent on the stimulus and cell type. Histone
deacetylases can influence Nox4 expression by regulating tran-
scription factor binding and miRNAs can influence mRNA levels
at the posttranscriptional level (Pendyala et al., 2011; Siuda et al.,
2012). A major limitation in our understanding of how Nox4
expression is regulated has been the lack and limited availability of
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specific Nox4 antibodies. A number of companies and individual
laboratories have generated antibodies to Nox4 with surprisingly
limited success (Zhang et al., 2011; Altenhofer et al., 2012). Given
the variety of epitopes used, it is unlikely that antigenicity is the
only barrier to success. More likely explanations include detergent
insolubility (Jagnandan et al., 2007) and the tendency of trans-
membrane proteins to form aggregates (Prive, 2007). Therefore,
studies using parallel approaches of real time PCR and Western
blots have provided the most convincing data.
While Nox4 is regarded as being constitutively active and
regulated in an inducible manner analogous to the inducible
nitric oxide synthase (iNOS), there are several proteins that have
been shown to modulate its activity. The best described of these
is p22phox. Loss of p22phox expression abrogates Nox4 activ-
ity, without significant changes in its expression level. Increased
expression of p22phox can also stimulate increased Nox4 activ-
ity. Poldip2 (polymerase DNA-directed delta-interacting protein
2) is a recently described protein that associates with p22phox to
increase Nox4 activity. The mechanism by which Poldip2 regu-
lates Nox4 activity is complex and involves not only the direct
binding to p22phox, but increased targeting of Nox4 to cytoskele-
tal regions (Lyle et al., 2009). The toll like receptor 4 (TLR4) was
found by yeast two hybrid and GST pull-down assays to interact
with Nox4. The C-terminal region of Nox4 binds to the cytoso-
lic region of TLR4 and mediates LPS-induced ROS production
(Park et al., 2004, 2006). Other post-translational modifications
of Nox4 are less well understood. In cells transfected with Nox4,
multiple bands have been detected on Western blots, and it has
been postulated that the larger band maybe result from glyco-
sylation of Nox4. Four putative sites of glycosylation have been
identified in the second and third extracellular loops of Nox4.
However, digestion with glycosidase did not support glycosyla-
tion (Shiose et al., 2001). More recent reports suggest that some
of the splice variants of Nox4 are glycosylated (Goyal et al.,
2005), however, definitive evidence on whether endogenously
expressed Nox4 or its variants are glycosylated is needed. Recently,
we reported that Small Ubiquitin-like Modifier (SUMO1) was
effective at suppressing Nox4 derived H2O2, but evidence of
direct SUMOylation of Nox enzymes was not observed suggest-
ing this is not a direct interaction (Pandey et al., 2011a). Protein
methylation inhibitors did not influence Nox4-derived ROS pro-
duction and the activity of Nox1 and 5, suggesting that protein
methylation does not regulate the activity of NADPH-oxidases
(Chen and Fulton, 2010). In native cells, the acute stimula-
tion of Nox4 has been shown in response to the PKC agonist
PMA in endothelial cells (Kuroda et al., 2005), angiotensin II
in renal mesangial and tubule cells (Gorin et al., 2003; Kim
et al., 2012), insulin in adipocytes (Mahadev et al., 2004), and
IGF-1 in VSMC (Xi et al., 2012). This data is contrasted by
results inmore controlled heterologous expression systems, where
Nox4 has been shown to be constitutively active and refractory
to PMA, agonist stimulation and other Nox subunits (with the
exception of p22phox) (Serrander et al., 2007; Helmcke et al.,
2009; Nisimoto et al., 2010; von Lohneysen et al., 2010; Chen
et al., 2011). The direct phosphorylation of Nox4 has not yet
been described but remains a possibility given that other Nox
isoforms are directly phosphorylated (Jagnandan et al., 2007;
Pandey and Fulton, 2011; Pandey et al., 2011b). Indeed, anal-
ysis of Nox4 amino acid sequence (NetPhos2, GPS) reveals the
presence of numerous PKC phosphorylation sites. Future stud-
ies will need to reconcile these observations and to determine
whether Nox4 is acutely responsive to agonists in native cells
and if so what factors are missing in the heterologous expression
systems.
SUBCELLULAR LOCALIZATION OF Nox4
The intracellular distribution localization of Nox4 has been
reported to influence a variety of Nox4 functions including
enzyme activity, the type of ROS emitted from cells and the acti-
vation of distinct downstream signaling pathways (Hilenski et al.,
2004; Kuroda et al., 2005; Serrander et al., 2007; Weyemi et al.,
2010). While this has generated significant interest in the subcel-
lular location of Nox4, it should not be surprising that this has
also been another area of disparity. Nox4 has been reported in
the nucleus of monocytes, endothelial and VSMC (Hilenski et al.,
2004; Ago et al., 2005; Pendyala et al., 2009; Lee et al., 2010), focal
adhesions in VSMC (Hilenski et al., 2004), the ER of transfected
HEK, COS cells, thyroid, endothelial cells and VSMC (Ambasta
et al., 2004; Van Buul et al., 2005; Martyn et al., 2006; Serrander
et al., 2007; Chen et al., 2008; Helmcke et al., 2009; von Lohneysen
et al., 2010; Weyemi et al., 2010; Wu et al., 2010), ER and nucleus
of smooth muscle cells and renal cortical cells (Sturrock et al.,
2007; Pendergrass et al., 2009), plasma membrane (PM) of lung
epithelial cells and transfected COS (von Lohneysen et al., 2008,
2010) and the mitochondria of mesangial and renal cortical cells,
cardiac myocytes and cancer cells (Block et al., 2009; Ago et al.,
2010; Graham et al., 2010; Kuroda et al., 2010). The reasons for
the different subcellular locations of Nox4 are likely to be mani-
fold. Cell type could be a factor, but the mechanisms responsible
for the cell type-specific targeting are unknown and it remains
unclear why motifs such as a putative mitochondrial localization
sequence (Graham et al., 2010) do not elicit mitochondrial target-
ing in all cell types. Nox4 has been shown to transition from one
intracellular compartment to another and thus it is possible that
some locations are transitory (Lyle et al., 2009; von Lohneysen
et al., 2010). Alternatively, some splice variants of Nox4 have been
reported to reside in the ER and others in the nucleus (Goyal
et al., 2005). This may explain the presence of Nox4 in multiple
intracellular compartments and the variation between cell types.
However, the relative abundance of these variants in different cells
is not known. Studies with fluorescent fusion proteins in live cells
have consistently revealed ER or PM staining (Ambasta et al.,
2004; von Lohneysen et al., 2010). Consistent with the results
from live cell experiments, epitope tagged forms of Nox4 and
NBT-staining of Nox4 in transfected cells have also revealed an
endomembrane/ER location (Serrander et al., 2007; Chen et al.,
2008; Helmcke et al., 2009). The live cell approach is devoid of
potential antibody problems or fixation/permeabilization arti-
facts but like epitope tagging, is also dependent on the proper
folding and targeting of the chimeric transgene and limited to
cell types amenable to transfection. Caution should be exercised
as the erroneous assignment of proteins to the nuclear or mito-
chondrial compartments has occurred for other proteins that are
clearly not present or functional in these organelles (Jagnandan
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et al., 2005). The underlying reasons for the diversity of intracel-
lular locations may relate to important cell-specific differences in
the function of Nox4 or it may simply be due to poorly selective
antibodies and or staining approaches. The development of a well
vetted, commercially available Nox4 antibody would aid in this
endeavor significantly.
Nox4 SIGNALING PATHWAYS AND REGULATION OF
CELLULAR FUNCTION
Nox4 has been reported to activate a number of kinases includ-
ing p38MAPK, Ras/ERK, JNK, and Akt (Djordjevic et al., 2005;
Wu et al., 2007; Chen et al., 2008; Goettsch et al., 2009; Jaulmes
et al., 2009). This may be due, at least in part, to the ability of
Nox4-derived H2O2 to oxidize the catalytic cysteine residues and
inhibit tyrosine phosphatases (Chen et al., 2008; Loh et al., 2009).
In unstimulated HEK cells, Nox4 can activate Erk1/2 and JNK sig-
naling pathways and Akt and p38 MAPK in response to challenge
with insulin (Anilkumar et al., 2008). These data suggest that
Nox4-dervived ROS can influence distinct signaling pathways that
depend on the presence or absence of agonists. In VSMC, Nox4
can activate the small GTPase Rho (Brown and Griendling, 2009)
which may be secondary to its ability to bind Poldip2 (Lyle et al.,
2009). Nox4 expression and H2O2 play important roles in medi-
ating oxygen sensing (Shiose et al., 2001), cell proliferation (Petry
et al., 2006), differentiation (Clempus et al., 2007), migration
(Lyle et al., 2009), apoptosis (Pedruzzi et al., 2004), senescence
(Geiszt et al., 2000), matrix secretion (Hecker et al., 2009), and
angiogenesis (Craige et al., 2011). The ability of Nox4 to regu-
late specific signaling pathways and cellular function appears to
be dependent on the level of Nox4 expression, the intracellular
location and the cell type. Given the high level of expression of
Nox4 in vascular cell and its proposed role in multiple cellular
processes, a surprising observation was that the genetic knock-
out of Nox4 did not result in an obvious baseline phenotype
(Kleinschnitz et al., 2010; Schroder et al., 2012). Blood pressure
(both systemic and pulmonary), cardiac function, endothelium-
dependent relaxation, cerebral blood flow, and kidney function
were unchanged in knockout mice.
THE ROLE OF Nox4 IN CARDIOVASCULAR DISEASES
Nox4 is expressed to varying degrees in virtually all cardiovascular
cell types and can, at least in culture, significantly impact cellular
function. In numerous cardiovascular diseases, such as hyperten-
sion, atherosclerosis, pulmonary and cardiac fibrosis, cardiac fail-
ure, stroke and diabetes, the expression level of Nox4 is elevated.
As Nox4 is constitutively active and regarded as an inducible Nox
or iNOX (Serrander et al., 2007), changes in expression suggest
changes in ROS levels. Ideally, both mRNA and proteins levels
should be assessed as similar to iNOS, it has been reported that
Nox4mRNA levels may not accurately reflect that of Nox4 protein
(Peshavariya et al., 2009). The following subsections will outline
current knowledge of the role of Nox4 in various cardiovascular
diseases. A summary of the literature is included in Table 1.
HYPERTENSION
Elevated blood pressure has long been associated with increased
ROS production in vascular tissue (Rajagopalan et al., 1996).
The abundant expression of Nox4 in vascular and renal cells has
led to numerous studies investigating its role in the elevation of
blood pressure. However, the importance of Nox4 in hyperten-
sion remains unclear. In cultured VSMC, the pressor hormone,
Angiotensin II increases Nox1 but not Nox4 expression (Lassegue
et al., 2001) and cyclic strain, which can mimic increased blood
pressure, decreases Nox4 in endothelial cells (Goettsch et al.,
2009). In animal models, Nox4 levels have been reported to be
decreased in the aorta of spontaneously hypertensive rats (SHR)
(Wind et al., 2010). In contrast, others have shown that Nox4
mRNA expression is 4.1-fold higher in basilar arteries from SHR
compared to normotensive Wistar-Kyoto rats (WKY) and in the
renal cortex of DOCA-salt rats (Nishiyama et al., 2004; Paravicini
et al., 2004). Thus, it is likely that the type of experimental
hypertension and the location of the blood vessel studied can
significantly impact how Nox4 expression is regulated. In the
absence of pathogenic stimuli, Nox4-knockout mice do not have
an obvious phenotype and are normotensive (Takac et al., 2012).
Furthermore, transgenic overexpression of Nox4 in the vascular
endothelium of mice lowers blood pressure (Ray et al., 2011). An
interesting observation in this study was that despite the obvious
higher level of Nox4 expression, endothelium-dependent relax-
ation was enhanced. This supports previous data showing that
Nox4 emits primarily H2O2 instead of O
·−
2 . A number of reports
have also shown that Nox4 can stimulate eNOS-derived nitric
oxide (NO·) (Craige et al., 2011; Schroder et al., 2012). The
increased endothelial expression of Nox5 which produces both
detectable O·−2 and H2O2 (Serrander et al., 2007), also resulted
in increased eNOS activity, but in marked contrast to Nox4, there
was significantly decreased biological effects of NO· due to the
interaction of NO· and O·−2 (Zhang et al., 2008). A complication
in the interpretation of overexpression strategies is that the level
of Nox4 and attendant ROS production is an important vari-
able and chronically high levels may stimulate feedback inhibition
and limit the endogenous expression of Nox4 with unpredictable
consequences on cellular function (Haurani et al., 2008).
ATHEROSCLEROSIS
Multiple Nox enzymes have been implicated in the development
of atherosclerotic plaques (Madamanchi and Runge, 2010). In
human atherosclerosis, Nox4 expression is increased in intimal
lesions of coronary arteries (Sorescu et al., 2002). However, in
experimental atherosclerosis, Nox4 protein levels are unchanged
in the aorta of genetically susceptible mice (Judkins et al., 2010)
or in primate models (Stanic et al., 2012). However, there is much
evidence in cell culture to suggest that Nox4 may be involved in
atherogenesis. Laminar flow which has been shown to be pro-
tective against atherosclerosis actually decreases Nox4 expression
(Goettsch et al., 2011) whereas oscillatory shear stress increases it
(Hwang et al., 2003). Moreover, a variety of oxidized lipids can
stimulate Nox4 expression. Oxidized LDL increases Nox4 expres-
sion in macrophages (Lee et al., 2009), 7-ketocholesterol stim-
ulates Nox4 expression in VSMC to induce ER stress (Pedruzzi
et al., 2004) and in endothelial cells, 1-palmitoyl-2-arachidonyl-
sn-glycerol-3-phosphocholine (Ox-PAPC) induces Nox4 expres-
sion (Lee et al., 2009). Despite these observations, a clear role
for Nox4 in atherosclerosis remains to be determined. It is
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Table 1 | Changes in Nox4 mRNA and protein expression and the effect of targeting Nox4 on cardiovascular diseases.
Disease Organism Nox4 Nox4 Intervention Effect on References
mRNA Protein disease
Cardiac failure Human ↑- – – – Dworakowski et al.,
2008; Borchi et al., 2010
Cardiac failure Mouse – ↑ Knockout ↓ Ago et al., 2010
Cardiac failure Mouse ↑ - – Knockout ↑ Byrne et al., 2003; Zhang
et al., 2010
Atrial fibrillation Human ↑ – None – Zhang et al., 2012
Stroke Mouse ↑ ↑ Knockout, Nox4
inhibitor
↓ Kleinschnitz et al., 2010
Pulmonary fibrosis Mouse ↑ ↑ Knockout, siRNA,
Nox4 inhibitor
↓ Hecker et al., 2009;
Carnesecchi et al., 2011
Pulmonary fibrosis Human ↑ ↑ None – Hecker et al., 2009;
Amara et al., 2010
Hypertension Rat ↑↓* – None – Nishiyama et al., 2004;
Paravicini et al., 2004;
Wind et al., 2010
Atherosclerosis Human ↑ ↑ None – Sorescu et al., 2002
Atherosclerosis Mouse – – None – Judkins et al., 2010
Diabetic renal injury Mouse – ↓ Knockout ↑ Babelova et al., 2012
Diabetic renal injury Mouse – ↑ Nox4 inhibitor ↓ Fibrosis Sedeek et al., 2010
Pulmonary hypertension Human ↑ ↑ None – Mittal et al., 2007; Li
et al., 2008
Pulmonary hypertension Mouse ↑ ↑ None – Mittal et al., 2007; Li
et al., 2008
*Vessel-dependent.
likely that Nox4 expression is influenced by a multitude of fac-
tors including the severity of the lesion (Sorescu et al., 2002),
the location of the blood vessel and individual factors such as
other concurrent diseases such as inflammation and heart fail-
ure (Guzik et al., 2006). More definitive studies are needed,
particularly with regard to the characterization of Nox4 expres-
sion in lesions of human blood vessels and in animal models of
atherosclerosis such as the diabetic pig (Gerrity et al., 2001) that
may better emulate advanced human atherosclerotic lesions using
genetic or pharmacological inhibition of Nox4.
PULMONARY ARTERIAL HYPERTENSION
Pulmonary Arterial Hypertension (PAH) arises from the nar-
rowing of pulmonary arteries which elevates pulmonary vascular
resistance and consequently pulmonary artery blood pressure.
The chronic elevation of pulmonary vascular resistance is sec-
ondary to occlusive remodeling of pulmonary blood vessels
(Humbert et al., 2004; Cool et al., 2005). PAH is characterized
by excessive proliferation and hypertrophy of pulmonary arterial
medial smooth muscle (Sturrock et al., 2006), adventitial remod-
eling (Stenmark et al., 2006) and the presence of plexiform lesions
(Tuder et al., 1994). ROS are important regulators of pulmonary
vascular remodeling, and abundant evidence supports a promi-
nent role for Nox4 in the pathogenesis of PAH (Mittal et al.,
2007; Nisbet et al., 2009). Nox4 is the major NADPH oxidase
homolog expressed in human pulmonary artery smooth mus-
cle cells (Sturrock et al., 2006), and its expression both at the
mRNA and protein level is significantly increased in lungs from
patients with idiopathic pulmonary arterial hypertension (IPAH)
compared to healthy lungs (Mittal et al., 2007), which suggests a
correlation between Nox4 and the onset of PAH.
In experimental models of PAH in rodents, Nox4 expres-
sion is also increased in chronic hypoxia-induced PAH in mice
(Mittal et al., 2007; Li et al., 2008; Nisbet et al., 2009) and
monocrotaline in rats (Dorfmuller et al., 2011). Nox4 mediates
the hypoxia-induced growth of human pulmonary smooth mus-
cle cells (Ismail et al., 2009), and silencing Nox4 expression by
RNA interference decreases human pulmonary arterial smooth
muscle cell and fibroblast proliferation (Sanders and Hoidal,
2007; Li et al., 2008; Griffith et al., 2009). Nox4 has been shown
to contribute to angiogenesis (Craige et al., 2011; Schroder et al.,
2012) and mediates the induction of VEGF and angiogenesis in
response to pressure overload in the heart (Zhang et al., 2010).
Severe forms of PAH are associated with plexiform lesions which
are comprised of proliferating endothelial cells and elevated lev-
els of angiogenic factors such as VEGF (Tuder et al., 2001; Jonigk
et al., 2011). Pneumonectomy increases the severity of PAH in
animals treated with monocrotaline and has been shown to stim-
ulate the formation of lesions that are morphologically similar to
plexiform lesions (Bauer et al., 2007). Pneumonectomy also fur-
ther increases the expression of Nox4 in monocrotaline-treated
animals (Dorfmuller et al., 2011), but it is not yet known whether
Nox4 is expressed in or contributes to the formation of these
lesions. Collectively, these findings support the argument for a
role of Nox4 in medial smooth muscle proliferation, endothelial
proliferation and adventitial fibroblast-activation in PAH. Nox4
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expression has been shown in the media of both normotensive
and hypertensive pulmonary arteries (Mittal et al., 2007). This
data is consistent with earlier reports of the location of Nox4 in
systemic arteries but contrasts from reports of higher expression
levels of Nox4 in endothelial cells and fibroblasts (Sorescu et al.,
2002; Ago et al., 2004; Schroder et al., 2012). This may reflect the
unique environment of the pulmonary circulation but warrants
additional investigation. Pulmonary blood pressure and right
ventricular systolic pressure in Nox4 knockout mice is unchanged
under normoxic conditions and hypoxic vasoconstriction in vitro
is equivalent to control mice (Kleinschnitz et al., 2010). Whether
pulmonary hypertension and remodeling of pulmonary arterioles
and the right ventricle in response to chronic hypoxia is altered
in the Nox4 knockout mouse is not yet known. It would also be
important to assess a role for Nox4 in additional models such as
the rat which develop amore robust pulmonary hypertension that
is closer to the human condition.
FIBROSIS
Nox4 is expressed in fibroblasts and expression is very strongly
induced by TGF-beta (Cucoranu et al., 2005; Hecker et al., 2009).
Hydrogen peroxide is a well-established pro-proliferative stimu-
lus (Davies, 1999) and Nox4, is the only Nox isoform that pref-
erentially emits H2O2. Nox4 expression in fibroblasts promotes
changes in proliferation, differentiation, migration, contractility,
and extracellular matrix secretion (Crestani et al., 2011). Nox4
expression is robustly increased in pulmonary fibroblasts from
patients with idiopathic pulmonary fibrosis and also in rodent
models (Hecker et al., 2009; Amara et al., 2010). Inhibition of
Nox4 using genetic or pharmacological approaches prevents lung
fibrosis (Hecker et al., 2009; Amara et al., 2010; Carnesecchi et al.,
2011) and suggests a prominent role for Nox4 in the pathogen-
esis of pulmonary fibrosis. However, others have reported that
some of the Nox4 knockout mice do not provide protection
against fibrosis (Altenhofer et al., 2012). An explanation for these
divergent findings has not been advanced and will likely only
be settled with additional studies using better tools. For exam-
ple, it has been reported that there are significant differences in
the Nox4 knockout models with regard to the targeting strategy
and whether Nox4 expression and activity is fully lost (Altenhofer
et al., 2012). The loss of Nox4 does not result in the upregula-
tion of other Nox proteins, but the Nox enzymes are only one
of many sources of cellular ROS. It remains to be determined
how the developmental loss of Nox4 impacts other sources of
ROS such as mitochondria, eNOS and other enzymes. More ele-
gant studies using inducible strategies in floxed mice would also
be advantageous to avoid developmental adaptation. The same
advantage would be derived from selective inhibitors of Nox4
with the added benefit that it could be employed in additional
organisms.
CARDIAC FAILURE
Nox4 is induced in experimental models of heart failure (Byrne
et al., 2003; Ago et al., 2010) and in humans (Dworakowski
et al., 2008). Recent studies using cardiac specific Nox4 knock-
out mice reveal decreased levels of ROS and improved perfor-
mance along with reduced hypertrophy, fibrosis and apoptosis.
Gain of function experiments using a transgenic cardiac specific
Nox4-overexpressing mouse had the opposite phenotype, pro-
moting dysfunction, fibrosis, and apoptosis in response to pres-
sure overload (Kuroda et al., 2010). While these results suggest
that Nox4 is a major source of oxidative stress involved in the
failing heart and is deleterious, others have shown the opposite
results using a global Nox4 knockout and a cardiac specific Nox4
transgenic (Zhang et al., 2010). A difference between these studies
is the method used to induce heart failure with transverse aor-
tic constriction of the ascending aorta used in the former and
abdominal constriction (descending) used in the latter. Further
studies are needed to determine how Nox4 may mediate such
contradictory roles.
STROKE
Elevated ROS have been linked to the severity of ischemic stroke
(Gilgun-Sherki et al., 2002). Nox isoforms including Nox4 are
expressed at much higher levels in cerebral vs. systemic blood ves-
sels (Miller et al., 2005). Nox4 expression is upregulated in human
and mouse brain post occlusion of the middle cerebral artery
(Kleinschnitz et al., 2010). Genetic deletion and pharmacologi-
cal inhibition of Nox4 reduced infarct volume, whereas genetic
deletion of Nox1 and Nox2 and treatment with apocynin had no
effect (Kleinschnitz et al., 2010). Therefore it is likely that Nox4 is
an important mediator of ischemia stroke. However, others have
shown that apocynin is effective against stroke and more specif-
ically that Nox2 may be important in ischemic stroke (Jackman
et al., 2009; Kahles and Brandes, 2012). While, there is much evi-
dence to support a role for Nox4 in stroke and other diseases,
controversy is unfortunately the most consistent theme through-
out. A good analogy is the parable of the blind men and the
elephant where unique and imperfect tools to study Nox4 lack
the necessary vision to provide an accurate picture that all can
agree on.
CONCLUDING REMARKS
In summary (see also Figure 1), there are three important aspects
to our understanding of Nox4. The first is that, Nox4 is truly
unique among the Nox isoforms. This is reflected by its high level
of expression in vascular cells, constitutive activity, subcellular
location, the pattern of ROS that it produces and its insensitiv-
ity to Hsp90 inhibitors. The second is that Nox4 is an inducible
Nox or iNox and its expression level is dynamically regulated in
response to a wide range of stimuli. The third is that we don’t yet
fully understand the physiological and pathophysiological roles
of Nox4. Expression levels of Nox4 are increased in a number
of diseases including fibrosis, PAH and stroke, but the functional
role ascribed to Nox4 is frequently both deleterious and beneficial
(Brandes et al., 2011; Altenhofer et al., 2012; Schmidt et al., 2012;
Schroder et al., 2012). This is an important conundrum and one
which can only be addressed properly with additional studies. In
cell culture, where the variables can be more tightly controlled,
there is a much clearer consensus on the functional role of Nox4.
In contrast, in animals, there are many possibilities to account
for the wide variation. These include the interaction of multi-
ple cell types that express Nox4, differences between the various
Nox4 knockout mice, developmental compensation for the loss
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of Nox4, a paucity of reliable inhibitors and the suitability of the
mouse as a model of cardiovascular disease. The latter is particu-
larly true with regard to PAH, where a number of rodent models
are necessary to emulate specific aspects of the human disease.
Mice are also inferior to rats for blood pressure research. Another
consideration is the assumption that changes in Nox4 expression
have a linear effect on cellular function. On the contrary, it is very
likely that the amount of ROS produced by Nox4 can have varying
effects with low levels of Nox4 expression having effects that are
quite distinct from high levels. There has been recent discussion
on whether Nox4 is good or bad and while this is understandable
given the current state of ambiguity in our understanding of
Nox4, it is also worth noting that there is little evolutionary pres-
sure to retain genes whose only function is to cause disease. In
contrast, the principles of toxicology are also worthy of consider-
ation in this debate as too much of a good thing can also be bad.
Certainly this is a well-established theme with regard to inflam-
mation and even endothelial nitric oxide synthase. Future studies
will be better served with improved tools including antibodies,
genetic models and inhibitors and these will all be necessary to
reveal the true nature of the role of Nox4 in both health and
disease.
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